•
Jun 30, 2022

Cencora Q3 2022 Earnings Report

AmerisourceBergen's revenue increased by 12.5% year-over-year, with GAAP diluted EPS of $1.92 and adjusted diluted EPS of $2.62.

Key Takeaways

AmerisourceBergen reported a strong third quarter with revenue increasing by 12.5% year-over-year to $60.1 billion. The company raised its full year outlook for adjusted diluted EPS to a range of $10.90 to $11.10.

Revenue increased 12.5 percent year-over-year to $60.1 billion.

GAAP diluted EPS was $1.92, compared to $1.40 in the prior year quarter.

Adjusted diluted EPS increased 21.3 percent to $2.62 from $2.16 in the prior year quarter.

Adjusted diluted EPS guidance has been raised to a range of $10.90 to $11.10 for fiscal year 2022.

Total Revenue
$60.1B
Previous year: $53.4B
+12.5%
EPS
$2.62
Previous year: $2.16
+21.3%
Effective Tax Rate
23.7%
Previous year: 48.5%
-51.1%
Adjusted Effective Tax Rate
20.2%
Previous year: 21%
-3.8%
Gross Profit
$2B
Previous year: $1.89B
+5.9%
Cash and Equivalents
$3.03B
Previous year: $2.55B
+18.8%
Free Cash Flow
$295M
Previous year: $1.09B
-72.8%
Total Assets
$57.2B
Previous year: $55.9B
+2.2%

Cencora

Cencora

Forward Guidance

AmerisourceBergen is updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of several of its businesses and a lower average diluted share count.

Positive Outlook

  • Adjusted Diluted Earnings Per Share to be in the range of $10.90 to $11.10, raised from the previous range of $10.80 to $11.05.
  • U.S. Healthcare Solutions operating income to be in the range of $2.44 billion to $2.48 billion, representing growth of 8% to 10%, raising the lower end of the previous range of $2.42 billion to $2.48 billion
  • Weighted average diluted shares to be in the range of 211 million to 211.5 million shares for the fiscal year, lowered from the previous range of approximately 212 million shares
  • Adjusted free cash flow to be in the range of $2.3 billion to $2.5 billion, raising the lower end of the previous range of $2.0 billion to $2.5 billion.
  • All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.